The Expression of NLK is Functionally Associated with Colorectal Cancers (CRC)

Overview

Journal J Cancer

Specialty Oncology

Date 2021 Nov 3

PMID 34729110

Citations 3

Authors

Xinyan Chen

Yifan Zhou

Yufeng Wan

Tingting Chen

Huaqing Zhu

Xiaowen Cheng

Affiliations

Soon will be listed here.

Abstract

The regulatory mechanism of NLK in the carcinomagenesis and progression of colorectal cancer (CRC) remains unclear. Here, we identified a single nucleotide polymorphism (SNP) site of NLK (rs2125846) as a new susceptibility locus for CRC risk located within an intron of the human NLK gene in a Chinese population. NLK downregulation led to a decrease in the ability of proliferation and migration of RKO cells . The proportion of RKO apoptotic cells increased by interfering with the endogenous expression of NLK. We speculate that LncRNA XIST may upregulate NLK expression by downregulating miR-92b-3p, thereby promote the development of CRC. These results provide important information for the identification of novel potential targets for the prevention or treatment of CRC.

Citing Articles

MSI2 regulates NLK-mediated EMT and PI3K/AKT/mTOR pathway to promote pancreatic cancer progression.

Huang L, Sun J, Ma Y, Chen H, Tian C, Dong M Cancer Cell Int. 2024; 24(1):273.

PMID: 39097735 PMC: 11297748. DOI: 10.1186/s12935-024-03444-9.

Canonical and noncanonical Wnt signaling: Multilayered mediators, signaling mechanisms and major signaling crosstalk.

Qin K, Yu M, Fan J, Wang H, Zhao P, Zhao G Genes Dis. 2023; 11(1):103-134.

PMID: 37588235 PMC: 10425814. DOI: 10.1016/j.gendis.2023.01.030.

The Potential Role of Small Nucleolar RNAs in Cancers - An Evidence Map.

Wu F, Zhang L, Wu P, Wu Y, Zhang T, Zhang D Int J Gen Med. 2022; 15:3851-3864.

PMID: 35431571 PMC: 9005336. DOI: 10.2147/IJGM.S352333.

References

Zhuang L, Yang Y, Ma X, Han B, Wang Z, Zhao Q . MicroRNA-92b promotes hepatocellular carcinoma progression by targeting Smad7 and is mediated by long non-coding RNA XIST. Cell Death Dis. 2016; 7:e2203. PMC: 4855645. DOI: 10.1038/cddis.2016.100. View

Millar D, Horan M, Chuzhanova N, Cooper D . Characterisation of a functional intronic polymorphism in the human growth hormone (GH1) gene. Hum Genomics. 2010; 4(5):289-301. PMC: 3500161. DOI: 10.1186/1479-7364-4-5-289. View

Han Y, Kuang Y, Xue X, Guo X, Li P, Wang X . NLK, a novel target of miR-199a-3p, functions as a tumor suppressor in colorectal cancer. Biomed Pharmacother. 2014; 68(5):497-505. DOI: 10.1016/j.biopha.2014.05.003. View

Huang Y, Yang Y, He Y, Li J . The emerging role of Nemo-like kinase (NLK) in the regulation of cancers. Tumour Biol. 2015; 36(12):9147-52. DOI: 10.1007/s13277-015-4159-7. View

Sun B, Liu C, Li H, Zhang L, Luo G, Liang S . Research progress on the interactions between long non-coding RNAs and microRNAs in human cancer. Oncol Lett. 2020; 19(1):595-605. PMC: 6923957. DOI: 10.3892/ol.2019.11182. View

Liu Y, Bodmer W . Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines. Proc Natl Acad Sci U S A. 2006; 103(4):976-81. PMC: 1327731. DOI: 10.1073/pnas.0510146103. View

Koncina E, Haan S, Rauh S, Letellier E . Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges. Cancers (Basel). 2020; 12(2). PMC: 7072488. DOI: 10.3390/cancers12020319. View

Lei L, Huang Y, Gong W . Inhibition of miR-92b suppresses nonsmall cell lung cancer cells growth and motility by targeting RECK. Mol Cell Biochem. 2013; 387(1-2):171-6. DOI: 10.1007/s11010-013-1882-5. View

Nass D, Rosenwald S, Meiri E, Gilad S, Tabibian-Keissar H, Schlosberg A . MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors. Brain Pathol. 2008; 19(3):375-83. PMC: 2728890. DOI: 10.1111/j.1750-3639.2008.00184.x. View

10.

Zhang Y, Peng C, Wu G, Wang Y, Liu R, Yang S . Expression of NLK and its potential effect in ovarian cancer chemotherapy. Int J Gynecol Cancer. 2011; 21(8):1380-7. DOI: 10.1097/IGC.0b013e3182262030. View

11.

Brott B, Pinsky B, Erikson R . Nlk is a murine protein kinase related to Erk/MAP kinases and localized in the nucleus. Proc Natl Acad Sci U S A. 1998; 95(3):963-8. PMC: 18639. DOI: 10.1073/pnas.95.3.963. View

12.

Long M, Zhan M, Xu S, Yang R, Chen W, Zhang S . miR-92b-3p acts as a tumor suppressor by targeting Gabra3 in pancreatic cancer. Mol Cancer. 2017; 16(1):167. PMC: 5659029. DOI: 10.1186/s12943-017-0723-7. View

13.

Shen C, Yan T, Wang Z, Su H, Zhu X, Tian X . Variant of SNP rs1317082 at CCSlnc362 (RP11-362K14.5) creates a binding site for miR-4658 and diminishes the susceptibility to CRC. Cell Death Dis. 2018; 9(12):1177. PMC: 6281592. DOI: 10.1038/s41419-018-1222-5. View

14.

Cheng L, Yang F, Zhou B, Yang H, Yuan Y, Li X . RAB23, regulated by miR-92b, promotes the progression of esophageal squamous cell carcinoma. Gene. 2016; 595(1):31-38. DOI: 10.1016/j.gene.2016.09.028. View

15.

Zhou M, Zhou H, Liu M, Sun J . The role of miR-92b in cholangiocarcinoma patients. Int J Biol Markers. 2018; 33(3):293-300. DOI: 10.1177/1724600817751524. View

16.

Khoury S, Tran N . Circulating microRNAs: potential biomarkers for common malignancies. Biomark Med. 2015; 9(2):131-51. DOI: 10.2217/bmm.14.102. View

17.

Wang K, Wang X, Zou J, Zhang A, Wan Y, Pu P . miR-92b controls glioma proliferation and invasion through regulating Wnt/beta-catenin signaling via Nemo-like kinase. Neuro Oncol. 2013; 15(5):578-88. PMC: 3635522. DOI: 10.1093/neuonc/not004. View

18.

Huang J, Wang B, Hui K, Zeng J, Fan J, Wang X . miR-92b targets DAB2IP to promote EMT in bladder cancer migration and invasion. Oncol Rep. 2016; 36(3):1693-701. DOI: 10.3892/or.2016.4940. View

19.

Min L, Chen L, Liu S, Yu Y, Guo Q, Li P . Loss of Circulating Exosomal miR-92b is a Novel Biomarker of Colorectal Cancer at Early Stage. Int J Med Sci. 2019; 16(9):1231-1237. PMC: 6775270. DOI: 10.7150/ijms.34540. View

20.

Yang W, Gu L, Yang C, Liu T . Expression of Nemo-like kinase in cervical squamous cell carcinoma: a clinicopathological study. Onco Targets Ther. 2018; 11:743-749. PMC: 5810516. DOI: 10.2147/OTT.S154188. View